Cargando…

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial

BACKGROUND: Little is known about the specific reasons for antipsychotic discontinuation or continuation from patients’ or clinicians’ perspectives. This study aimed to assess the construct validity of 2 new measures of the Reasons for Antipsychotic Discontinuation/Continuation (RAD): RAD-I (a struc...

Descripción completa

Detalles Bibliográficos
Autores principales: Faries, Douglas, Ascher-Svanum, Haya, Phillips, Glenn, Nyhuis, Allen W, Sugihara, Tomoko, Stauffer, Virginia, Kinon, Bruce J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505169/
https://www.ncbi.nlm.nih.gov/pubmed/22974273
http://dx.doi.org/10.1186/1471-2288-12-142
_version_ 1782250724279713792
author Faries, Douglas
Ascher-Svanum, Haya
Phillips, Glenn
Nyhuis, Allen W
Sugihara, Tomoko
Stauffer, Virginia
Kinon, Bruce J
author_facet Faries, Douglas
Ascher-Svanum, Haya
Phillips, Glenn
Nyhuis, Allen W
Sugihara, Tomoko
Stauffer, Virginia
Kinon, Bruce J
author_sort Faries, Douglas
collection PubMed
description BACKGROUND: Little is known about the specific reasons for antipsychotic discontinuation or continuation from patients’ or clinicians’ perspectives. This study aimed to assess the construct validity of 2 new measures of the Reasons for Antipsychotic Discontinuation/Continuation (RAD): RAD-I (a structured interview assessing the patient’s perspective) and RAD-Q (a questionnaire assessing the clinician’s perspective). METHODS: Data were used from a 12-week antipsychotic trial of schizophrenia patients in which the RAD was administered at study entry and at study completion (or discontinuation). Construct validity was assessed through comparisons of RAD responses, clinicians’ responses to a standard patient disposition form identifying reasons for patient’s study discontinuation, and several standard psychiatric measures. Percent agreement quantified the correspondence between patient and clinician scores. RESULTS: Patients indicating lack of improvement/worsening of positive symptoms as a ‘somewhat’ to ‘primary’ reason for medication discontinuation had statistically significantly less improvement in Positive and Negative Syndrome Scale positive score than patients not reporting these as a reason (concurrent validity). Similar results were observed for the RAD negative symptom, functional, social support, and adherence items, whereas the mood and cognitive items were not significantly associated with change scores on standard psychiatric measures. Responses to the RAD were also weakly associated with variables that theoretically should not be related to them (divergent validity). Level of agreement between the clinician- and patient-rated RAD scores was high (60%-100%). CONCLUSIONS: Initial validation of the RAD suggests that the instruments are valid tools for gathering detailed information regarding reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives.
format Online
Article
Text
id pubmed-3505169
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35051692012-11-24 Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial Faries, Douglas Ascher-Svanum, Haya Phillips, Glenn Nyhuis, Allen W Sugihara, Tomoko Stauffer, Virginia Kinon, Bruce J BMC Med Res Methodol Research Article BACKGROUND: Little is known about the specific reasons for antipsychotic discontinuation or continuation from patients’ or clinicians’ perspectives. This study aimed to assess the construct validity of 2 new measures of the Reasons for Antipsychotic Discontinuation/Continuation (RAD): RAD-I (a structured interview assessing the patient’s perspective) and RAD-Q (a questionnaire assessing the clinician’s perspective). METHODS: Data were used from a 12-week antipsychotic trial of schizophrenia patients in which the RAD was administered at study entry and at study completion (or discontinuation). Construct validity was assessed through comparisons of RAD responses, clinicians’ responses to a standard patient disposition form identifying reasons for patient’s study discontinuation, and several standard psychiatric measures. Percent agreement quantified the correspondence between patient and clinician scores. RESULTS: Patients indicating lack of improvement/worsening of positive symptoms as a ‘somewhat’ to ‘primary’ reason for medication discontinuation had statistically significantly less improvement in Positive and Negative Syndrome Scale positive score than patients not reporting these as a reason (concurrent validity). Similar results were observed for the RAD negative symptom, functional, social support, and adherence items, whereas the mood and cognitive items were not significantly associated with change scores on standard psychiatric measures. Responses to the RAD were also weakly associated with variables that theoretically should not be related to them (divergent validity). Level of agreement between the clinician- and patient-rated RAD scores was high (60%-100%). CONCLUSIONS: Initial validation of the RAD suggests that the instruments are valid tools for gathering detailed information regarding reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives. BioMed Central 2012-09-13 /pmc/articles/PMC3505169/ /pubmed/22974273 http://dx.doi.org/10.1186/1471-2288-12-142 Text en Copyright ©2012 Faries et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Faries, Douglas
Ascher-Svanum, Haya
Phillips, Glenn
Nyhuis, Allen W
Sugihara, Tomoko
Stauffer, Virginia
Kinon, Bruce J
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
title Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
title_full Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
title_fullStr Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
title_full_unstemmed Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
title_short Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
title_sort construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505169/
https://www.ncbi.nlm.nih.gov/pubmed/22974273
http://dx.doi.org/10.1186/1471-2288-12-142
work_keys_str_mv AT fariesdouglas constructvalidityof2measurestoassessreasonsforantipsychoticdiscontinuationandcontinuationfrompatientsandcliniciansperspectivesinaclinicaltrial
AT aschersvanumhaya constructvalidityof2measurestoassessreasonsforantipsychoticdiscontinuationandcontinuationfrompatientsandcliniciansperspectivesinaclinicaltrial
AT phillipsglenn constructvalidityof2measurestoassessreasonsforantipsychoticdiscontinuationandcontinuationfrompatientsandcliniciansperspectivesinaclinicaltrial
AT nyhuisallenw constructvalidityof2measurestoassessreasonsforantipsychoticdiscontinuationandcontinuationfrompatientsandcliniciansperspectivesinaclinicaltrial
AT sugiharatomoko constructvalidityof2measurestoassessreasonsforantipsychoticdiscontinuationandcontinuationfrompatientsandcliniciansperspectivesinaclinicaltrial
AT stauffervirginia constructvalidityof2measurestoassessreasonsforantipsychoticdiscontinuationandcontinuationfrompatientsandcliniciansperspectivesinaclinicaltrial
AT kinonbrucej constructvalidityof2measurestoassessreasonsforantipsychoticdiscontinuationandcontinuationfrompatientsandcliniciansperspectivesinaclinicaltrial